Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities

Thermosensitive Liposomes for Gemcitabine Delivery to Pancreatic Ductal Adenocarcinoma

Treatment of pancreatic ductal adenocarcinoma with gemcitabine is limited by an increased desmoplasia, poor vascularization, and short plasma half-life. Heat-sensitive liposomes modified by polyethylene glycol (PEG; PEGylated liposomes) can increase plasma stability, reduce clearance, and decrease side effects. Nevertheless, translation of heat-sensitive liposomes to the clinic has been hindered by the low loading efficiency of gemcitabine and by the difficulty of inducing hyperthermia in vivo. This study was designed to investigate the effect of phospholipid content on the stability of liposomes at 37 °C and their release under hyperthermia conditions; this was accomplished by employing a two-stage heating approach. First the liposomes were heated at a fast rate, then they were transferred to a holding bath. Thermosensitive liposomes formulated with DPPC: DSPC: PEG2k (80:15:5, mole%) exhibited minimal release of carboxyfluorescein at 37 °C over 30 min, indicating stability under physiological conditions. However, upon exposure to hyperthermic conditions (43 °C and 45 °C), these liposomes demonstrated a rapid and significant release of their encapsulated content. The encapsulation efficiency for gemcitabine was calculated at 16.9%. Additionally, fluorescent analysis during the removal of unencapsulated gemcitabine revealed an increase in pH. In vitro tests with BxPC3 and KPC cell models showed that these thermosensitive liposomes induced a heat-dependent cytotoxic effect comparable to free gemcitabine at temperatures above 41 °C. This study highlights the effectiveness of the heating mechanism and cell models in understanding the current challenges in developing gemcitabine-loaded heat-sensitive liposomes.

Cr(VI) and doxorubicin adsorptive capture by a novel bionanocomposite of Ti-MOF@TiO2 incorporated with watermelon biochar and chitosan hydrogel

Biodegradable polymers, biochars and metal organic frameworks (MOFs) have manifested as top prospects for elimination of harmful pollutants. In the current study, Ti-MOF was synthesized and decorated with TiO2 nanoparticles, then embedded into watermelon peel biochar and functionalized with chitosan hydrogel to produce Ti-MOF@TiO2@WMPB@CTH. Various instruments were employed to assure the effective production of the bionanocomposite. The HR-TEM and SEM studies referred to excellent surface porosity and homogeneity of Ti-MOF@TiO2@WMPB@CTH bionanocomposite, with 51.02-74.23 nm. Based on the BET analysis, the mesoporous structure has a significant surface area of 366.04 m2 g-1 and a considerable total pore volume of 11.38 × 10-2 cm3 g-1, with a mean pore size of 12.434 nm. Removal of doxorubicin (DOX) and hexavalent chromium (Cr(VI)) was examined under various experimentations. Pseudo-second order kinetic models in addition to Langmuir isotherm offered the best fitting. Thermodynamic experiments of the two contaminants demonstrated spontaneous and endothermic interactions. After five subsequent adsorption and desorption cycles, Ti-MOF@TiO2@WMPB@CTH bionanocomposite demonstrated an exceptional recyclability for the elimination of DOX and Cr(VI) ions, reaching 97.96 % and 95.28 %, respectively. Finally, the newly designed Ti-MOF@TiO2@WMPB@CTH bionanocomposite demonstrated a high removing efficiency of Cr(VI) ions and DOX from samples of real water.

Review of the Delivery Kinetics of Thermosensitive Liposomes

Thermosensitive liposomes (TSL) are triggered nanoparticles that release the encapsulated drug in response to hyperthermia. Combined with localized hyperthermia, TSL enabled loco-regional drug delivery to tumors with reduced systemic toxicities. More recent TSL formulations are based on intravascular triggered release, where drug release occurs within the microvasculature. Thus, this delivery strategy does not require enhanced permeability and retention (EPR). Compared to traditional nanoparticle drug delivery systems based on EPR with passive or active tumor targeting (typically <5%ID/g tumor), TSL can achieve superior tumor drug uptake (>10%ID/g tumor). Numerous TSL formulations have been combined with various drugs and hyperthermia devices in preclinical and clinical studies over the last four decades. Here, we review how the properties of TSL dictate delivery and discuss the advantages of rapid drug release from TSL. We show the benefits of selecting a drug with rapid extraction by tissue, and with quick cellular uptake. Furthermore, the optimal characteristics of hyperthermia devices are reviewed, and impact of tumor biology and cancer cell characteristics are discussed. Thus, this review provides guidelines on how to improve drug delivery with TSL by optimizing the combination of TSL, drug, and hyperthermia method. Many of the concepts discussed are applicable to a variety of other triggered drug delivery systems.